Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT IN MYMD PHARMACEUTICALS, INC. (Details Narrative)

v3.24.3
INVESTMENT IN MYMD PHARMACEUTICALS, INC. (Details Narrative) - USD ($)
3 Months Ended
May 20, 2024
Jul. 31, 2024
Jul. 31, 2023
May 23, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Payment for investment   $ 7,000,000 $ (0)  
[custom:GainOnRelatedPartyInvestmentTNF]   21,395,734 0  
[custom:ChangeInFairValueOfInvestmentTnf]   724,266 $ 0  
TNF Series G Preferred Stock [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment Owned, Fair Value       $ 17,410,000
TNF Warrants [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment Owned, Fair Value       $ 10,986,000
T N F [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment Owned, Fair Value   18,377,000    
[custom:ChangeInFairValueOfInvestmentTnf]   529,266    
[custom:WarrantAssetTNF-0]   $ 10,743,000    
Securities Purchase Agreement [Member] | TNF Pharmaceuticals Inc [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Payment for investment $ 7,000,000      
Securities Purchase Agreement [Member] | TNF Pharmaceuticals Inc [Member] | TNF Series G Preferred Stock [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment shares owned 7,000      
Number of common shares issuable upon conversion of preferred stock 3,854,626      
Securities Purchase Agreement [Member] | TNF Pharmaceuticals Inc [Member] | TNF Warrants [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Investment shares owned 3,854,626